Skip to main content
Erschienen in: Rheumatology International 6/2006

01.04.2006 | Original Article

Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations?

verfasst von: U. Musabak, S. Pay, H. Erdem, I. Simsek, A. Pekel, A. Dinc, A. Sengul

Erschienen in: Rheumatology International | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Interleukin (IL)-18 is a proinflammatory cytokine which plays a crucial role in T helper (Th)1 type immune response. The aim of this study is to investigate the relationship of serum levels of IL-18 with disease activity and clinical presentations in patients with Behcet’s disease (BD). Sixty patients with BD and 20 healthy controls were included in the study. Patients were grouped as having active or inactive disease according to the Leeds activity score. They were also separated as a systemic involvement or mucocutaneous symptoms only. Patients with systemic involvement were further grouped according to the presence of ocular, articular and vascular involvement. IL-18 levels were significantly higher in all patient subgroups as compared to healthy controls and found to be correlated with the activity score in patients having active disease. In conclusion, this cytokine participates in the pathogenesis of BD and its levels are correlated with the disease activity. Detection of increased levels of IL-18 in patients with inactive disease implies that Th1 activation and subclinical inflammation persist during the inactive period of the disease.
Literatur
1.
Zurück zum Zitat Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61:100–102CrossRefPubMed Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61:100–102CrossRefPubMed
2.
Zurück zum Zitat Liew FY, Wei XQ, McInnes IB (2003) Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 62:48–50CrossRef Liew FY, Wei XQ, McInnes IB (2003) Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 62:48–50CrossRef
3.
Zurück zum Zitat Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285CrossRefPubMed Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285CrossRefPubMed
4.
Zurück zum Zitat Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474CrossRefPubMed Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474CrossRefPubMed
5.
Zurück zum Zitat Dinerallo CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(suppl27):S1–S13 Dinerallo CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(suppl27):S1–S13
6.
7.
Zurück zum Zitat Matsui K, Tsutsui H, Nakanishi K (2003) Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets 7:701–724CrossRefPubMed Matsui K, Tsutsui H, Nakanishi K (2003) Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets 7:701–724CrossRefPubMed
8.
Zurück zum Zitat Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB (2001) A role for IL-18 in neutrophil activation. J Immunol 167: 2879–2886PubMed Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB (2001) A role for IL-18 in neutrophil activation. J Immunol 167: 2879–2886PubMed
9.
Zurück zum Zitat Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB (2003) Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339–347CrossRefPubMed Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB (2003) Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 48:339–347CrossRefPubMed
10.
Zurück zum Zitat Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443CrossRefPubMed Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443CrossRefPubMed
11.
Zurück zum Zitat Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81:1371–1383PubMed Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81:1371–1383PubMed
12.
Zurück zum Zitat Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, McInnes IB, Liew FY (2003) Chemoattraction of human T cells by IL-18. J Immunol 170:1084–1090PubMed Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, McInnes IB, Liew FY (2003) Chemoattraction of human T cells by IL-18. J Immunol 170:1084–1090PubMed
13.
Zurück zum Zitat Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644–1653PubMed Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644–1653PubMed
14.
Zurück zum Zitat Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, Nakanishi K, Tateishi H, Maruo S, Okamura H (2002) Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 25(Suppl1):S61–S64CrossRefPubMed Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, Nakanishi K, Tateishi H, Maruo S, Okamura H (2002) Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 25(Suppl1):S61–S64CrossRefPubMed
15.
Zurück zum Zitat Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, Kakishita E (2000) Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 109:652–657CrossRefPubMed Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, Kakishita E (2000) Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 109:652–657CrossRefPubMed
16.
Zurück zum Zitat Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 44:550–560CrossRefPubMed Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 44:550–560CrossRefPubMed
17.
Zurück zum Zitat Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63:1300–1306CrossRefPubMed Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63:1300–1306CrossRefPubMed
18.
Zurück zum Zitat Behçet H (1937) Uber rezidivierende apthose, durch ein virus verursachte geschwure am mund, am auge und an den genitalien. Dermatol Wochenschr 105:1152–1157 Behçet H (1937) Uber rezidivierende apthose, durch ein virus verursachte geschwure am mund, am auge und an den genitalien. Dermatol Wochenschr 105:1152–1157
19.
Zurück zum Zitat Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974CrossRefPubMed Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974CrossRefPubMed
20.
Zurück zum Zitat Alpsoy E, Cayirli C, Er H, Yilmaz E (1998) The levels of plasma interleukin-2 and soluble interleukin-2R in Behcet’s disease: a marker of disease activity. J Dermatol 25:513–516PubMed Alpsoy E, Cayirli C, Er H, Yilmaz E (1998) The levels of plasma interleukin-2 and soluble interleukin-2R in Behcet’s disease: a marker of disease activity. J Dermatol 25:513–516PubMed
21.
Zurück zum Zitat Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205–210CrossRefPubMed Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205–210CrossRefPubMed
22.
Zurück zum Zitat Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Detection of gamma interferon in the sera of patients with Behcet’s disease. Infect Immun 36:202–208PubMed Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Detection of gamma interferon in the sera of patients with Behcet’s disease. Infect Immun 36:202–208PubMed
23.
Zurück zum Zitat Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Studies on spontaneous production of gamma-interferon in Behcet’s disease. Ophthalmologica 185:187–192PubMedCrossRef Ohno S, Kato F, Matsuda H, Fujii N, Minagawa T (1982) Studies on spontaneous production of gamma-interferon in Behcet’s disease. Ophthalmologica 185:187–192PubMedCrossRef
24.
Zurück zum Zitat Bacon TH, Ozbakir F, Elms CA, Denman AM (1984) Interferon-gamma production by peripheral blood mononuclear cells from patients with Behcet’s syndrome. Clin Exp Immunol 57:541–547PubMed Bacon TH, Ozbakir F, Elms CA, Denman AM (1984) Interferon-gamma production by peripheral blood mononuclear cells from patients with Behcet’s syndrome. Clin Exp Immunol 57:541–547PubMed
25.
Zurück zum Zitat Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet’s disease. Invest Ophthalmol Vis Sci 39:996–1004PubMed Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet’s disease. Invest Ophthalmol Vis Sci 39:996–1004PubMed
26.
Zurück zum Zitat Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S (1998) Divergent cytokine production profile in Behcet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25:329–333PubMed Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S (1998) Divergent cytokine production profile in Behcet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25:329–333PubMed
27.
Zurück zum Zitat Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003) Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet’s disease. J Dermatol 30:602–607PubMed Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003) Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet’s disease. J Dermatol 30:602–607PubMed
28.
Zurück zum Zitat Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S (1996) Cytokines in Behcet’s disease. J Rheumatol 23:321–322PubMed Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S (1996) Cytokines in Behcet’s disease. J Rheumatol 23:321–322PubMed
29.
Zurück zum Zitat Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet’s disease. J Rheumatol 17:1428–1429PubMed Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet’s disease. J Rheumatol 17:1428–1429PubMed
30.
Zurück zum Zitat Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549PubMed Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549PubMed
31.
Zurück zum Zitat Hamzaoui A, Ghrairi H, Ammar J, Zekri S, Guemira F, Hamzaoui K (2003) IL-18 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet’s disease. Clin Exp Rheumatol 21(Suppl30):S8–S14PubMed Hamzaoui A, Ghrairi H, Ammar J, Zekri S, Guemira F, Hamzaoui K (2003) IL-18 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet’s disease. Clin Exp Rheumatol 21(Suppl30):S8–S14PubMed
32.
Zurück zum Zitat International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080PubMed International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080PubMed
33.
Zurück zum Zitat Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behcet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behcet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef
34.
Zurück zum Zitat Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B (2005) Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet’s disease. Clin Exp Dermatol 30:61–63CrossRefPubMed Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B (2005) Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet’s disease. Clin Exp Dermatol 30:61–63CrossRefPubMed
35.
Zurück zum Zitat Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatolgy 42:860–864CrossRef Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatolgy 42:860–864CrossRef
Metadaten
Titel
Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations?
verfasst von
U. Musabak
S. Pay
H. Erdem
I. Simsek
A. Pekel
A. Dinc
A. Sengul
Publikationsdatum
01.04.2006
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 6/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0029-8

Weitere Artikel der Ausgabe 6/2006

Rheumatology International 6/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.